Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity
GLP-1 (glucagon-like peptide-1) receptor agonists are medications designed to regulate blood sugar, reduce appetite, and slow digestion
These ongoing studies will provide valuable insights into the optimal use of this triple agonist for managing obesity and related metabolic disorders
Most protocols run 2 to 6 sessions depending on the area and the patients response, spaced anywhere from 7 days to 4 weeks apart
Patients should contact their healthcare provider if mucus in stool is accompanied by any of the following warning signs: Immediate medical attention is recommended for: Severe, persistent abdominal pain, especially if radiating to the back or accompanied by nausea/vomiting (possible pancreatitis) Blood in stool (red blood or black, tarry stools) Right upper quadrant pain, especially with fever or yellowing of skin/eyes (possible gallbladder disease) Fever above 100.4F (38C) Signs of dehydration (decreased urination, dizziness, extreme thirst, dry mouth) Unintentional weight loss beyond expected therapeutic effects Persistent vomiting preventing adequate fluid intake Schedule a routine appointment if experiencing: Mucus in stool persisting beyond 1-2 weeks Significant changes in bowel habits (frequency, consistency, or appearance) Mucus accompanied by persistent bloating or discomfort New onset of symptoms after stable medication tolerance Concerns about symptom severity or impact on quality of life Healthcare providers will typically conduct a thorough clinical assessment including detailed history, physical examination, and potentially laboratory investigations
